To the Editor The recently published Original Investigation by Lintzeris and colleagues¹ about nabiximols for the treatment of cannabis dependence reported that cannabinoid agonist medication reduces illicit cannabis use among cannabis-dependent persons. We have some concerns about how the authors represented their data, leading us to believe that such a conclusion is not justified. The authors appear to have switched primary outcomes between study registration and publication, thereby inaccurately portraying the trial results.

中文翻译：

---

纳比西莫斯治疗大麻依赖性的临床意义和结果。

致编辑最近由Lintzeris及其同事发表的有关萘比莫索用于治疗大麻依赖的原始调查¹报道，大麻素激动剂可减少大麻依赖者之间的非法大麻使用。我们担心作者如何表示他们的数据，使我们相信这样的结论是没有道理的。作者似乎在研究注册和发表之间切换了主要结局，因此对试验结果的描述不准确。